Enhertu showed better outcomes in HR-positive, HER2-negative breast cancer, while Trodelvy was more effective in HR-negative, HER2-null tumors when used first. Real-world data from over 4,000 patients ...
Researchers developed a tool to predict chemotherapy response for patients with triple-negative breast cancer. Researchers at The University of Texas MD Anderson Cancer Center have developed a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results